Combating Resistance in Antibiotic Drug Discovery and Development

Hosted By: Pharma IQ
Rate this Podcast: 
Be the first!
To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

About this Podcast...

The epidemiology of increasing resistance problem continues to garner much attention. A bacteria capable of opposing the inhibitory (bacteriostatic) or killing (bacteriocidal) effects of antibiotics has unfortunately become an increasingly common occurrence and presents a serious threat to successful treatment of bacterial infections.

In this interview Dr. Mark Brian Anderson, Chief Scientific Officer at NovaBay Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about the growing market demand for novel anti-infective drugs and the key scientific challenges to antibiotic drug discovery and development.  Anderson also shares his insights on what  the industry is doing to combat resistance, which presents a huge market inhibitor.


Crowne Plaza Zurich, Zurich, Switzerland
June 17 - 19, 2018